Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.50 |
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1664336 | 0.86 | ESR1 (0.60) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1666112 | 0.84 | PDE10A (0.53) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1663442 | 0.81 | ESR1 (0.50) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL10446409 | 0.80 | ESR1 (0.49) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1663008 | 0.79 | ESR1 (0.53) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1663101 | 0.78 | ALDH1A1 (0.45) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1665671 | 0.77 | ALDH1A1 (0.49) | PDE10AESR1ESR2TRPV1LMNA | |
| SCHEMBL1663630 | 0.77 | ESR1 (0.57) | PDE10AESR1ESR2TRPV1MAPK1 | |
| SCHEMBL1663398 | 0.77 | TRPV1 (0.72) | PDE10AESR1ESR2TRPV1MAPK1 | |
| SCHEMBL1663648 | 0.77 | ESR1 (0.53) | PDE10AESR1ESR2TRPV1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| CN-101356160-A | Trisubstituted quinazolinone derivatives as vanilloid antagonists | JANSSEN PHARMACEUTICA NV (CH) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | PDE10A 1942/4885ESR1 1321/4885ESR2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.